Evidence map›Paper›PMID 39360810›Full record

ArticleCancer research communications2024

High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis.

Annie Wai Yeeng Chai, Yee Hua Tan, Shiyin Ooi, Pei San Yee, Shi Mun Yee, Howard Lightfoot, Syd Barthorpe, Mathew J Garnett, Sok Ching Cheong

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Annie Wai Yeeng ChaiTranslational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.ORCID 0000-0002-8015-6050
Yee Hua TanTranslational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.ORCID 0009-0001-8753-5408
Shiyin OoiTranslational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.ORCID 0000-0002-6165-111X
Pei San YeeTranslational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.ORCID 0000-0002-6548-2149
Shi Mun YeeTranslational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.ORCID 0009-0007-9858-1817
Howard LightfootWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.ORCID 0000-0003-2082-9986
Syd BarthorpeWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.ORCID 0009-0002-5155-0646
Mathew J GarnettWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.ORCID 0000-0002-2618-4237
Sok Ching CheongTranslational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.ORCID 0000-0002-6765-9542

Funding

Wellcome Trust
6 · The paper itself

Abstract

significanceMechanistically guided drug repurposing has been made possible by systematically integrating pharmacologic and CRISPR-Cas9 screen data. Our study discovers the biomarker and cell death mechanisms underpinning sensitivity toward AZD5582, an antagonist of the inhibitor of apoptosis family protein. Our findings have important implications for improving future trial design for patients with OSCC using this emerging drug class.

Indexed as

ApoptosisCaspase 8NF-kappa BTumor Necrosis Factor-alphaCarcinoma, Squamous CellCell Line, TumorDrug RepositioningHumansMouth NeoplasmsSignal TransductionCASP8 protein, humanCaspase 8NF-kappa BTNF protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID39360810
PMCPMC11551840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.